NCT04759365View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 2, 2021

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

ASN51

ASN51 formulation for oral capsule

DRUG

Placebo

Placebo formulation for oral capsule

Trial Locations (1)

3004

Nucleus Network, Melbourne

Sponsors
All Listed Sponsors
collaborator

Asceneuron S.A.

INDUSTRY

collaborator

Neuroscience Trials Australia

OTHER

lead

Asceneuron Pty Ltd.

INDUSTRY

NCT04759365 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease | Biotech Hunter | Biotech Hunter